Clearside Biomedical Inc

Here is the public summary page for Clearside Biomedical Inc. Please login to see the complete information for Clearside Biomedical Inc including detailed analysis of price, sentiment, fundamentals, flow, forecast models, alerts and much more. Also you can see how Clearside Biomedical Inc stacks up relative to its peers.


Darwin Score+13
TickerCLSD
Latest Price0.45 USD as of close on 30-Jul-2025
3 Month price range0.74 to 0.90 USD
Market Capitalisation63.12Mn USD
CountryUnited States of America
RegionNorth America
Economic SectorHealth Care
Business SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryPharmaceuticals
Sub-IndustryPharmaceuticals
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
See More ...
Company URLhttps://clearsidebio.com
See Darwins Full Analysis for Clearside Biomedical Inc

Tell Me About

Tell Me About (TMA) is Darwins structured scoring system for assets. Here are the scores from the key TMA sections for Clearside Biomedical Inc. Further information and full detail is available when you login.

TMA PartFocus of AnalysisTMA Score
PriceAnalysis of performance, trend, RSI, OBV and moving averages+7
SentimentNews and Candle Patterns. 0
FundamentalsAnalyst Ratings, Valuation and Dividend analysis.+3
FlowInstitutional, Fund and Insider buying and selling.+2
ModelsForecast models.+1

Share Share on Facebook Share on Twitter Share on Threads Share on LinkedIn